The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how integrating genomic features improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia (OM-CMML). She explains how specific mutation patterns help distinguish OM-CMML from myelodysplastic syndromes (MDS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
